CHP
VRTX icon

Cable Hill Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Cable Hill Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$471K Sell
924
-101
-10% -$47.1K 0.05% 97
2024
Q4 		$413K Buy
1,025
+1
+0.1% +$464 0.04% 104
2024
Q3 		$476K Buy
1,024
+7
+0.7% +$3.36K 0.05% 92
2024
Q2 		$477K Buy
+1,017
New +$441K 0.05% 91
2023
Q4 		– Sell
-1,173
Closed -$408K – 245
2023
Q3 		$408K Buy
1,173
+187
+19% +$65.4K 0.06% 87
2023
Q2 		$347K Sell
986
-267
-21% -$90K 0.05% 114
2023
Q1 		$395K Sell
1,253
-35
-3% -$10.5K 0.06% 99
2022
Q4 		$372K Buy
1,288
+26
+2% +$7.92K 0.07% 108
2022
Q3 		$365K Buy
1,262
+141
+13% +$40.6K 0.07% 87
2022
Q2 		$316K Buy
1,121
+183
+20% +$49K 0.08% 100
2022
Q1 		$245K Buy
938
+9
+1% +$2.14K 0.16% 106
2021
Q4 		$204K Buy
+929
New +$181K 0.04% 149
2019
Q2 		– Sell
-219
Closed -$40K – 685
2019
Q1 		$40K Sell
219
-12
-5% -$2.22K 0.01% 282
2018
Q4 		$38K Buy
231
+11
+5% +$1.91K 0.02% 273
2018
Q3 		$41K Sell
220
-230
-51% -$41K 0.02% 206
2018
Q2 		$76K Sell
450
-37
-8% -$5.74K 0.03% 142
2018
Q1 		$75K Sell
487
-66
-12% -$10.8K 0.03% 146
2017
Q4 		$85K Sell
553
-73
-12% -$10.8K 0.04% 160
2017
Q3 		$95K Buy
626
+482
+335% +$72.5K 0.04% 169
2017
Q2 		$18K Buy
144
+124
+620% +$14.9K 0.01% 279
2017
Q1 		$2K Hold
20
– – ﹤0.01% 686
2016
Q4 		$1K Sell
20
-5
-20% -$407 ﹤0.01% 705
2016
Q3 		$2K Buy
25
+5
+25% +$473 ﹤0.01% 728
2016
Q2 		$2K Buy
+20
New +$1.73K ﹤0.01% 641

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cable Hill Partners's VRTX Position: Q1 2025 in Review

Cable Hill Partners reduced its Vertex Pharmaceuticals (VRTX) stake by 9.9% in Q1 2025, selling an estimated $47.1K and leaving 924 shares worth $471K. The position accounts for 0.05% of the portfolio, ranked #97.

Cable Hill Partners first reported a position in VRTX in Q2 2016 and has held it in 24 quarters since. The position peaked at $477K in Q2 2024. 1,613 funds tracked by Wall St. Rank hold VRTX as of Q1 2025.

  • Cable Hill Partners held 924 shares of Vertex Pharmaceuticals worth $471K as of Q1 2025.
  • Cable Hill Partners sold 101 Vertex Pharmaceuticals shares in Q1 2025, an estimated $47.1K.
  • Vertex Pharmaceuticals made up 0.05% of Cable Hill Partners's portfolio in Q1 2025, its #97 holding.
  • Cable Hill Partners first reported a position in Vertex Pharmaceuticals in Q2 2016 and has held it in 24 quarters since.
  • Cable Hill Partners's Vertex Pharmaceuticals position peaked at $477K in Q2 2024.
  • 1,613 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2025.

Based on Cable Hill Partners's 13F filing for Q1 2025, filed 2 May 2025.